Chai Discovery partners with GSK
Following successful wet-lab evaluations, Chai provides its AI protein models to accelerate GSK's drug discovery pipeline across therapeutic targets.
See the latest news and media coverage for Chai. We track all announcements, press releases, and industry mentions in real time, all in one place.
Artificial intelligence platform for computer-aided molecular design
chaidiscovery.comLast updated
In short: Chai raised $400M, valuing it at $3.8 billion, and signed multiple pharma collaborations for its AI antibody design.
Following successful wet-lab evaluations, Chai provides its AI protein models to accelerate GSK's drug discovery pipeline across therapeutic targets.
The round will advance AI-driven molecular design for drug discovery.
Led by General Catalyst and Oak HC/FT, with Thrive Capital, OpenAI, and others participating. Annie Lamont and Hemant Taneja join the board. Funds support research and team growth.
Chai-2 designs full-length mAbs with high developability, atomic precision via Cryo-EM, and success against hard targets like GPCRs and peptide-MHC.
AstraZeneca acquires global rights to approved EGFR exon 20 inhibitor Zegfrovy, Chai Discovery...
Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with biopharma company GSK following a successful technology evaluation...
A month after Chai Discovery tied up a major $400 million series C funding round, the AI drug discovery firm has teamed up with Bristol...
The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to ...
Track Chai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Chai and other trending companies.